Spero Therapeutics (SPRO) Financials

$1.22

$-0.01 (-0.81%)

As on 26-Aug-2026 16:00EDT

Market cap

$70 Mln

Revenue (TTM)

$43 Mln

P/E Ratio

8.6

P/B Ratio

1.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	42.96	59.62	47.98	103.78	48.58	3.07
Cost of Revenue	--	--	96.76	51.44	1.55	1.12
Gross Profit	42.96	59.62	-48.78	52.34	48.58	3.07
Operating Expenses	36.94	59.64	24.58	30.86	90.78	91.04
Operating Profit (EBIT)	6.03	-0.02	-73.36	21.48	-42.20	-87.97
Other Income	--	--	--	--	--	--
Profit before Tax	7.64	8.83	-68.57	25.40	-46.42	-89.76
Provision for Tax	0.26	0.26	--	2.60	1.61	1.55
Profit after Tax (Net Income)	7.38	8.57	-68.57	22.81	-46.42	-89.76
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-46.42	-89.76

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	44.20	59.02	46.12	106.89	75.93	88.29
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.13	1.03	15.35	38.34	27.22	64.11
Current Liabilities	8.43	8.87	49.07	37.15	21.65	18.67
Total Liabilities	61.19	68.92	110.54	182.39	124.80	171.07

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	1.18	1.63	3.27	51.18	15.70	13.20
Current Assets	51.58	67.29	107.28	131.21	109.11	157.87
Total Assets	104.35	68.92	110.54	182.39	124.80	171.07
Total Debt*	2.04	2.90	4.30	5.54	6.65	7.34
Net Current Assets	--	58.42	58.20	94.06	91.92	139.20

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-12.62	-23.44	-33.00	-7.73	-64.35
Cash Flow from Investing Activities	--	--	--	--	33.81	7.67
Cash from Financing Activities	--	--	--	0.22	-29.55	84.05
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	0.11	0.14	-1.27	0.43	-0.95	-2.79
Cash EPS ($)	--	0.14	-1.27	0.44	-0.93	-2.77
Adjusted Book Value ($)	--	0.99	0.85	2.01	1.56	2.75
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.21	-0.43	-0.62	-0.16	-2.00
Free Cash Flow per Share ($)	--	-0.21	-0.43	-0.62	-0.16	-2.00

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	15.26	-84.20	23.39	-52.09	-76.23
ROE (%)	14.30	16.31	-89.62	24.95	-56.53	-81.47
ROA (%)	8.14	9.55	-46.81	14.85	-31.37	-55.32
EBIT Margin (%)	-17.06	--	-151.08	25.81	-90.18	-2,860.46
Net Margin (%)	17.18	14.38	-142.91	21.98	-95.55	-2,923.65
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	-6.98	0.24	-0.54	1.14	14.82	-0.67
EBIT Growth (%)	86.70	--	-370.59	161.14	50.11	-11.00
Net Profit Growth (%)	113.77	112.50	-400.65	149.13	48.29	-15.79
EPS Growth (%)	111.10	1.11	-3.95	1.45	0.66	0.01
Book Value Growth (%)	30.14	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	8.64	16.14	-0.81	3.42	-1.82	-5.73
Price / Book Value	1.59	2.34	1.21	0.73	1.11	5.83
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	3.29	11.43	-0.10	0.27	0.42	-4.31
Close Price ($)	2.21	2.33	1.03	1.47	1.73	16.01
High Price ($)	3.22	3.22	1.89	2.04	16.30	22.24
Low Price ($)	1.80	0.51	0.92	0.99	0.68	11.75
Market Cap ($ Cr)	70.46	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.05	0.09	0.05	0.09	0.08
Short term debt to equity ratio	0.05	0.03	0.04	0.02	0.02	0.02
Current Ratio	6.12	7.59	2.19	3.53	5.04	8.46
Quick Ratio	6.12	--	--	3.53	5.25	8.48
Interest Coverage	--	--	--	--	-16.82	-45.27

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	0.06	42.58	109.38	48.85	2.23	86.03
Asset Turnover	0.47	0.66	0.33	0.68	0.33	0.02
Receivable days	--	238.51	392.73	91.12	14.00	524.50
Inventory Days	--	--	0.00	-15.84	-569.48	-2,060.05
Payable days	--	--	16.39	7.08	202.81	368.85
Cash Conversion Cycle	--	--	376.34	68.19	-758.29	-1,904.40

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.